The Belmont Report is a foundational document in research ethics that lays out three core principles for protecting people who participate in scientific studies: Respect for Persons, Beneficence, and Justice. Published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, it remains the ethical backbone of human subjects research in the United States and has shaped research regulations worldwide.
Why the Belmont Report Was Created
The Belmont Report exists because of a decades-long research scandal. Between 1932 and 1972, the U.S. Public Health Service ran a study on untreated syphilis in Tuskegee, Alabama. Researchers enrolled Black men in the study without obtaining informed consent. Even after penicillin became widely available as an effective treatment for syphilis, the researchers withheld it from participants so they could continue observing the disease’s progression.
The study ended in 1972 only after journalists exposed it publicly. An advisory panel convened by the Assistant Secretary for Health and Scientific Affairs recommended shutting it down. The fallout was immediate. In 1974, Congress passed the National Research Act, which created the National Commission and tasked it with identifying the basic ethical principles that should govern all biomedical and behavioral research involving human subjects. The Commission spent nearly four years in monthly discussions, including an intensive four-day deliberation in 1976, before publishing the Belmont Report.
Research vs. Medical Practice
One of the report’s first tasks was drawing a clear line between research and routine medical care, because the ethical obligations differ. Medical practice refers to interventions designed solely to benefit an individual patient, with a reasonable expectation of success. Your doctor prescribing a well-established medication for your blood pressure is practice.
Research, by contrast, is designed to test a hypothesis and produce generalizable knowledge. It follows a formal protocol with a defined objective and specific procedures to reach that objective. A clinical trial testing whether a new drug lowers blood pressure more effectively than an existing one is research. This distinction matters because research carries unique risks: the intervention may not help you personally, and the primary goal is generating data, not treating your condition. The Belmont Report argues that whenever an activity falls into the research category, it needs a higher level of ethical scrutiny and oversight.
Principle 1: Respect for Persons
This principle rests on two convictions. First, individuals should be treated as autonomous agents, meaning they have the right to make their own informed decisions about whether to participate in a study. Second, people with diminished autonomy (such as children, people with cognitive disabilities, or prisoners) deserve additional protections because they may not be fully able to advocate for themselves.
In practice, Respect for Persons translates into the requirement for informed consent. This isn’t just getting someone to sign a form. The report identifies three components that must all be present. Participants need adequate information about what the study involves, including its purpose, procedures, and risks. They need to genuinely comprehend that information, which means researchers can’t bury critical details in dense legal language or rush through an explanation. And their agreement must be voluntary, free from coercion or undue pressure. A participant who feels they’ll lose access to medical care if they refuse, for example, isn’t truly volunteering.
Principle 2: Beneficence
Beneficence goes beyond simply being kind to research participants. The Belmont Report treats it as a strict obligation with two rules: do not harm, and maximize possible benefits while minimizing possible harms. Researchers can’t simply hope their study won’t hurt anyone. They’re required to actively think through the risks beforehand and design the study to reduce them.
This obligation extends beyond individual investigators to institutions and society as a whole. Before a study begins, researchers and their institutions must systematically assess the risks and potential benefits. That means weighing not just physical risks like side effects, but also psychological, social, and economic harms that participants might experience. If the risks outweigh the potential benefits, the study shouldn’t move forward, regardless of how scientifically interesting it might be.
Principle 3: Justice
Justice addresses a simple but powerful question: who bears the burdens of research, and who reaps the benefits? The Tuskegee study was a stark example of injustice. Poor, rural Black men shouldered all the risks while the medical knowledge gained would primarily benefit the broader population. They were selected not because of any scientific rationale but because they were vulnerable and easy to exploit.
The Justice principle requires that the selection of research subjects be fair. Researchers shouldn’t target populations simply because they’re convenient, easily manipulated, or socially disadvantaged. Equally, the benefits that come from research should be accessible to the communities that helped generate them. If a new treatment is developed through trials conducted in low-income communities, those communities shouldn’t be priced out of the resulting therapy.
How the Report Shapes Research Today
The Belmont Report’s principles aren’t just aspirational. They’re built into the regulatory framework that governs research across the United States. In 1981, the Department of Health and Human Services and the Food and Drug Administration used the report as their foundation to revise federal human subjects regulations. In 1991, those regulations became the Federal Policy for the Protection of Human Subjects, commonly known as the Common Rule, which 15 federal departments and agencies adopted.
The Common Rule requires that any institution receiving federal funding for human subjects research establish an Institutional Review Board, or IRB. These boards review every proposed study before it can begin, evaluating it against the Belmont principles. They examine whether the informed consent process is adequate, whether the risks are justified by the potential benefits, and whether participants are being selected fairly. No federally funded study involving human subjects can proceed without IRB approval.
Each of the three Belmont principles maps to a specific application that IRBs evaluate. Respect for Persons drives the review of informed consent procedures. Beneficence drives the assessment of risks and benefits. Justice drives the scrutiny of how and why specific populations are being recruited. This structure gives review boards a consistent framework for evaluating studies across every field, from psychology experiments to cancer drug trials.
Why It Still Matters
If you’re enrolling in a clinical trial, the Belmont Report is the reason you’ll receive a detailed consent form explaining the study’s purpose, procedures, risks, and your right to withdraw at any time without penalty. It’s the reason an independent board reviewed the study’s design before anyone was recruited. And it’s the reason researchers can’t specifically target vulnerable populations simply because they’re less likely to object.
The report is remarkably short, just a few thousand words, and it doesn’t prescribe specific rules or procedures. Instead, it provides the ethical reasoning that rules and procedures are built on. That’s part of why it has lasted. Technologies, research methods, and social norms have changed dramatically since 1979, but the core questions the Belmont Report asks (are participants making informed, voluntary choices? are the risks justified? is the burden shared fairly?) remain relevant to every study involving human beings.